Abbvie Inc.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
25.44%
Market Cap
364.14 Bil.
P/E Ratio
96.78
Dividend Yield
2.91 %
Earnings per Share
2.09 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 206.1 G | 0 Units |
| PRICE DETERMINATION TIME | 06/23/2026 / 09:56:30 PM | |
| DAILY VOLUME (UNITS) | 362 | |
| DAILY HIGH / LOW | 206.3 | 200.4 |
| PREV. DAY'S PRICE | 201.2 | (06/22) |
| CHANGE DAY BEFORE | +4.90 | 2.44 % |
| 52 WEEK HIGH / LOW | 208 (10/02) | 156 (06/30) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 14.17 | 12.43 | 2.09 | 2.21 | 2.51 |
| DIVIDENDS PER SHARE | 6.34 | 6.03 | 5.89 | 5.81 | 5.54 |
| DIVIDEND YIELD IN % | - | - | 2.91 % | 3.54 % | 3.87 % |
| DIVIDEND GROWTH IN % | - | - | 1.37 % | 4.95 % | 2.04 % |
| PRICE - EARNINGS RATIO | 13.32 | 15.19 | 96.78 | 74.34 | 57.00 |
| PRICE - BOOK RATIO | - | - | - | 94.34 | 26.42 |
| PRICE - SALES RATIO | - | - | 6.62 | 5.59 | 5.06 |
| PRICE - CASH FLOW RATIO | - | - | 21.29 | 16.75 | 12.05 |
Master Data
| WKN | A1J84E |
| ISIN | US00287Y1091 |
| SYMBOL | 4AB |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Abbvie |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 1.77 Bil. |
| MARKET CAPITALISATION | 364.14 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 5.34 % | 8.06 % | 13.67 % | 3.93 % | 25.44 % | 60.70 % | 108.63 % | 2.86 % |
| HIGH | 202.80 | 202.80 | 202.80 | 203.00 | 208.00 | 208.00 | 208.00 | 203.00 |
| LOW | 187.80 | 181.15 | 166.65 | 166.65 | 156.00 | 119.10 | 89.97 | 166.65 |
Dividend
per share
Company profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Structured products for Abbvie Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.